Liquid chromatography high-resolution mass spectrometry (LC-HRMS) with untargeted data collection is especially attractive for general unknown drug screening owing to its ability to identify unexpected compounds. LC-HRMS offers several advantages over traditional selected reaction monitoring (SRM) techniques and could be an ideal screening platform as long as its analytical performance is comparable to that of SRMbased methods.
long as the analytical performance is able to match or exceed that of SRM-based methods.
To date, a number of studies have compared the performance of high-resolution and nominal mass instruments for broad-spectrum drug screening (4 -11 ) . Many of the high-resolution methods in these prior studies use "all-ions fragmentation" to generate product ions. A major disadvantage of this approach is that product ion spectra are contaminated by coeluting compounds, since all ions are sent to the collision cell and fragmented at the same time. Although individual precursor-product ion transitions can be used for compound identification, structural information and product ion lineage is lost, making it more difficult to identify unknown or unexpected compounds.
By selecting precursor ions before fragmentation, methods that use information-dependent acquisition (IDA) (or DDA, for data-dependent acquisition) produce high-quality product ion spectra that are less affected by coeluting compounds. Product ion spectra may also provide higher confidence in compound identification than individual precursor-product ion transitions. IDA-based methods are often used to screen for a large number of drugs, especially when compound identification is more important than quantification (12) (13) (14) (15) (16) (17) (18) (19) (20) . Although several studies have investigated the performance of high-resolution instruments from which IDA-product ion spectra are obtained (21) (22) (23) (24) (25) (26) (27) , to the best of our knowledge, none have compared their performance to that of nominal mass SRM-IDA methods.
The objective of this study was to determine if a high-resolution method with untargeted data collection could be used as an alternative to a nominal mass SRM-IDA method for GUS. We developed a broad-spectrum drug screen on a tandem quadruple time-of-flight (QqTOF) instrument which collected data in full-scan TOF-MS mode with IDA acquisition of product ion spectra. We then compared its performance to our existing QqLIT method, which collected data in SRM-IDA mode. Both methods were kept consistent; we used the same sample preparation, LC method, and data analysis software for both. We determined the matrix effects and lower limits of detection (LODs) for each method and compared the methods on the basis of their ability to identify drugs and metabolites in 100 routine clinical urine samples by targeted data analysis.
Methods

STANDARDS AND REAGENTS
Acetonitrile, methanol, formic acid, and ammonium formate were analytical grade and purchased from Fisher Scientific or Sigma-Aldrich. We purchased drug standards and labeled internal standards from Cerilliant, Grace Davison/Alltech, Sigma-Aldrich, and Lipomed and human drug-free urine from UTAK Laboratories.
SAMPLE PREPARATION
We added 40 L internal standard (100 g/mL fentanyl-d5 or benzoylecgonine-d8 in 100% methanol) to 9.96 mL of 12.5% 50:50 acetonitrile:methanol in water. Samples were diluted by a factor of 5 (1 part sample plus 4 parts diluent for a final sample concentration of 20%) and the resulting mixture was run according to the methods described below. We used internal standards to monitor assay performance (e.g., retention time and peak intensity).
QqLIT METHOD
All samples were injected (10 L injection volume) onto the LC QqLIT system. Chromatographic separation was performed on an Agilent 1200 series LC system with a Phenomenex Kinetex 2.6-m C18 column (3 ϫ 50 mm) maintained at 30°C. A binary mobile phase consisting of 0.05% formic acid in 5 mmol/L ammonium formate in water (A) and 0.05% formic acid in 50:50 methanol/acetonitrile (B) was ramped linearly from 2% to 98% B over 10 min. The column was washed at 100% B for 2 min, followed by a 2-min reequilibration at 2% B. The flow rate was 400 L/min. Data were collected with a 3200 QTrap ® equipped with a TurboIon Spray™ source controlled by Analyst 1.5.1 software (ABSciex). We performed positive ionization with the following settings: ion spray voltage, 5500 V; curtain gas, 20 psi; ion source gas 1, 40 psi; ion source gas 2, 40 psi; collisionally activated dissociation gas, high; interface heater temperature, 40°C; declustering potential, 40 V; and entrance potential, 10 V.
We collected data by use of a scheduled SRM scan followed by collection of enhanced product ion (EPI) spectra when a compound met IDA criteria. The scheduled SRM window was 1 min. The method contained 169 transitions. We performed dynamic background subtraction of the survey scan. Fragmentation was performed in the collision cell (Q2) with a collision energy spread of 35 (15) V. We set IDA criteria to select for the 3 most intense peaks that exceeded 400 cps. Former target ions were excluded for 15 s after 3 occurrences. The mass tolerance was set to 250 mDa, and the EPI scan rate was 4000 Da/s. Q0 trapping was enabled, and the LIT fill time was set to 50 ms.
QqTOF METHOD
Chromatographic separation was performed on a Shimadzu Prominence LC-20ADXR system with the same column, mobile phases, gradient, and injection volume as described for the QqLIT method. Data were collected with a 5600 QTOF system equipped with an ESI source controlled by Analyst 1.5.1 (ABSciex). Ionization was performed with the following settings: ion source gas 1, 30 psi; ion source gas 2, 30 psi; curtain gas, 25 psi; temperature, 500°C; ion spray voltage floating, 5500 V; and declustering potential, 100 V. The method consisted of a TOF MS full scan from 50 to 700 Da and IDA-triggered acquisition of product ion spectra (IDA threshold 100 counts per second) for Յ20 candidate ions per cycle. The instrument was operated at a mass resolution of approximately 30 000 for the TOF MS scan (at m/z 300) and approximately 15 000 for the product ion scan in highsensitivity mode. Automatic calibrations were performed with the atmospheric pressure chemical ionization DuoSpray source probe and automatic calibrant delivery system, which injected manufacturer-supplied calibration solution every 5 injections.
METHOD VERIFICATION
We determined the LOD by spiking drug standards into drug-free urine at various concentrations (5, 10, 25, 50, 100, 125, 250, and 500 ng/mL). Samples were injected in duplicate. The LOD was defined as the lowest concentration at which 2 criteria were met in both injections: (a) the drug was called positive by our scoring criteria and (b) the signal-to-noise ratio was Ͼ20:1.
We determined matrix effects by spiking drug standards into 3 different matrices (charcoal-stripped, drugfree urine, and urine from 2 healthy individuals) at 100 or 500 ng/mL. Samples were injected in triplicate, producing a total of 9 data points for each drug. Peak intensities were recorded and compared to that of the drug spiked in water. Matrix effects were calculated with the following equation: (B -A)/A ϫ 100%, where B is the mean signal intensity in urine and A is the signal intensity in water.
We obtained 100 remnant urine samples from the clinical laboratory at San Francisco General Hospital after routine drug screening. This study was approved by the University of California-San Francisco Committee on Human Research, which deemed that patient consent was not required. After obtaining patient prescription information, immunoassay results, and LC-MS/MS or GC-MS confirmation results, samples were deidentified according to institutional review board protocol. Cloned enzyme donor immunoassays for the cocaine metabolite (benzodiazepine), methadone metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), amphetamines/ Ecstasy, benzodiazapines, and opiates were used. Samples that screened positive for opiates were confirmed by GC-MS as described by Wang et al. (28 ) . Samples that screened positive for amphetamines were confirmed by LC-MS/MS for the presence of amphetamine, methamphetamine, methylenedioxymethamphetamine, and methylenedioxyamphetamine as described by Drees et al. (29 ) .
All patient urine samples were also run on an Orbitrap mass spectrometer. For this method, the sample preparation, chromatographic gradient, mobile phases, and flow rate were the same as for the QqLIT and QqTOF methods described above. Chromatographic separation was performed with a CTC PAL autosampler and 2 Thermo Scientific Series 600 Transcend pumps. Full-scan data from 50 to 700 Da was collected with all-ions fragmentation. Compounds were identified by comparing the precursor mass, retention time, and 2 product ion masses to that of drug standards. The allowable error for compound identification was 10 ppm for the precursor mass and 0.5 min for the retention time.
DATA ANALYSIS
We performed data analysis with the MasterView function (version 1.0) in PeakView ® software (version 2.0, ABSciex). QqTOF data were analyzed in a targeted manner for the same 169 compounds that were included in the QqLIT method. Data were searched against a spectral library that was built in-house and contained both nominal mass and high-resolution product ion spectra.
For the QqTOF data, extracted ion chromatograms were generated with a 30-ppm precursor mass search window, a 0.5-min retention time search window, and a minimum peak intensity of 1 count per second. Candidate ions that met this initial search criteria were then scored on the basis of how well their precursor mass, retention time, isotope pattern, and product ion spectrum matched what was expected for a particular compound. The mass and retention time scores depend on the extracted-ion chromatogram search window. The isotope pattern and product ion spectrum scores are generated by proprietary fitting algorithms. After individual scores were generated for each parameter, they were weighted and summed to generate a combined score between 0 and 100.
A drug or metabolite was called positive if the combined score was Ն70 as generated by 1 of the following equations, depending on the instrument used:
QqLIT combined score ϭ 50% (retention time score) ϩ 50% (library score); QqTOF combined score ϭ 10% (mass score) ϩ 10% (retention time score) ϩ 10% (isotope score) ϩ 70% (library score).
The weighting parameters in these equations and the score cutoff of 70 were determined by systematically analyzing the scores of known samples (our LOD samples). Finally, structural isomers that had similar retention times and product ion spectra often both met the score cutoff for positivity. In these instances, the compound with the higher score was chosen so that only 1 compound was called positive per chromatographic peak. To compare the performance of QqLIT and QqTOF methods, 100 patient urine samples were analyzed by both methods for the same 169 compounds. All additional information about these samples (results obtained from the Orbitrap, immunoassay screens, GC-MS and/or LC-MS/MS confirmation assays, and patient prescription history) was used to confirm discordant results between the QqLIT and the QqTOF. A drug was confirmed if the parent or metabolite was detected by 1 of the other methods. Drugs and metabolites were grouped and counted only as the "reportable drug." For instance, if benzoylecgonine and/or cocaine was detected in a patient's sample, it was counted only as cocaine. Although this may obscure some minor variations in analytical performance, we were most interested in comparing the clinically relevant results produced by each method.
Results
LOD
LODs were established for each method. For QqTOF, 39% of compounds had an LOD of 5 ng/mL, 19% had an LOD of 10 ng/mL, and 12% had an LOD of 25 ng/mL. For QqLIT, 51% had an LOD of 5 ng/mL, 14% had an LOD of 10 ng/mL, and 11% had an LOD of 25 ng/mL. When the LODs for individual drugs were examined, QqLIT and QqTOF had the same LODs for 76 compounds; QqTOF LOD was lower for 33 drugs, and QqLIT LOD was lower for 60 drugs (Fig. 1A) . Overall, the QqLIT method was more analytically sensitive than QqTOF, but in many cases, this was a difference of only 5 ng/mL (20 drugs) or 15 ng/mL (8 drugs) (Fig. 1B) .
MATRIX EFFECTS
Most compounds were suppressed by matrix on the QqTOF method; the mean (SD) matrix effect for the QqTOF method was Ϫ25% (63%). For reference, no ion suppression or ion enhancement equaled 0% matrix effect. Some compounds (olanzapine, prochlorperazine, and diphenoxylate) were enhanced Ͼ200% relative to water. The matrix effects observed with the QqLIT method were similar, but overall, compounds were not as suppressed by matrix compared with the QqTOF method. The mean (SD) matrix effect was 3% (76%). Similarly, a few compounds (diphenoxylate, prochlorperazine, desipramine, and mescaline) were enhanced Ͼ200% by matrix compared with water (see Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol62/ issue1).
PATIENT COMPARISON SAMPLES
The QqLIT method identified a total of 596 drugs in the urine samples, of which 531 (89%) were confirmed (Table 1). The QqTOF method identified 515 drugs, of which 500 (97%) were confirmed. Overall, there were 562 instances of a confirmed drug (68 unique drugs) in the 100 patient urine samples. The methods were concordant in 469 of these instances. There were 62 instances of a confirmed positive that was found by QqLIT but missed by QqTOF. These 62 instances included only 33 unique drugs, so certain drugs were repeatedly missed by QqTOF but found by QqLIT, including hydrocodone (missed 5 times), hydromorphone (4 times), morphine (4 times), clonazepam (3 times), and diphenhydramine (3 times). There were 31 instances of a confirmed positive that was found by QqTOF but missed by QqLIT. These 31 instances included 24 unique drugs; most of the drugs detected by the QqTOF only were single occurrences.
Discussion
LC-HRMS with untargeted data collection is especially attractive in the setting of GUS because of its ability to identify unexpected compounds. LC-HRMS has the potential to be an ideal stand-alone screening platform as long as it can match or exceed the analytical performance of traditional SRM-based methods when using targeted data analysis. In this study, we compared the performance of a high-resolution instrument (QqTOF) that collected untargeted data to that of a nominal mass instrument (QqLIT) that collected data in SRM-IDA mode. Although we observed some minor differences in analytical sensitivity between these 2 methods, overall, QqTOF performed similarly to QqLIT in identifying drugs and metabolites in 100 clinical urine samples and, (13) 1 (13) therefore, could serve as an alternative to SRM-based methods in broad-spectrum drug screening. First, we found that a high proportion of the drugs identified by QqTOF (500 of 515, or 97%) were confirmed by another method. In contrast, only 89% of the compounds identified by QqLIT were confirmed by another method. This difference in specificity may be due to how the data are acquired, specifically in the survey scan. In the QqTOF method, compound selection is based on the precursor's exact mass, whereas in the QqLIT method, compound selection is based on the detection of a precursor-to-product ion transition. The specificity of the QqLIT method relies on carefully selecting transitions, such that each is unique to the compound. However, only nonspecific transitions occur for some analytes, which may explain the difference in specificity between the 2 methods. This difference in specificity has important implications in the clinical laboratory; identifying compounds with high confidence in the initial screen reduces the need for follow-up testing, which can be costly and prolong turnaround times. It is also possible that the unconfirmed positives identified by QqTOF or QqLIT are actually true positives that were missed by the other confirmatory methods. A major limitation of any GUS evaluation is the lack of a gold standard method for comparison. We also found that QqTOF was slightly less sensitive than QqLIT. Other references have reported a similar trend regarding the sensitivity of high-resolution, untargeted methods compared to nominal mass, targeted methods (9, 11, 30 ) . Although this result may seem surprising, a QqLIT instrument operating in SRM mode is one of the most sensitive methods for targeted analysis because the data acquisition time is dedicated to a specific list of compounds. In contrast, QqTOF acquisition time is spread out over thousands of ions.
Despite this difference in analytical sensitivity, we did not observe a significant effect on compound detection in the patient samples. Only some of the compounds that were missed by QqTOF but found by QqLIT could be attributed to the lower sensitivity of QqTOF. For example, clonazepam was missed multiple times due to differences in the LOD of its metabolite, 7-aminoclonazepam (LOD 25 ng/mL by QqLIT vs 100 ng/mL by QqTOF). But for many compounds, the difference in LOD between the 2 methods was only 5 or 15 ng/mL (Fig. 1B) , which did not produce significant differences in qualitative results. In most cases, the analytical sensitivity of the QqTOF method was sufficient to identify drugs and metabolites in real samples.
The QqTOF method did miss some compounds because it failed to acquire product ion spectra. Although QqTOF instruments can collect a large number of IDA experiments, these experiments may be occupied by matrix components rather than toxicologically relevant compounds, especially in complex samples such as urine and serum. Therefore, compounds detected in the TOF-MS survey scan at the expected mass and retention time may not trigger fragmentation, as was the case with about one-third of the QqLIT-positive/QqTOFnegative compounds. This is a known limitation of IDAbased methods. A better sample cleanup may improve detection, as it would remove matrix contaminants and allow QqTOF to spend more time collecting data on relevant compounds. In addition, alternative ways to collect product ions have been proposed [e.g., sequential window acquisition of all theoretical fragment-ion spectra (SWATH) and all-ions fragmentation]. These tech- niques have been shown to collect more product ion spectra than IDA; however, the quality of spectra is worse, since spectra are contaminated by coeluting compounds (31 ) . A "contaminated" spectrum may not be detrimental to compound identification by targeted analysis, but it is unclear how it will affect the identification of unexpected or unknown compounds, which is the main selling point of HRMS. Further work must be done to determine the appropriate use of these techniques with clinical samples, as each method has its advantages and disadvantages. Analytically speaking, the value of HRMS with untargeted data collection is its ability to identify compounds that are unexpected or unknown. But we found that QqTOF provided several practical benefits as well (Table 2 ). In terms of data-processing time and complexity, we observed no differences between QqTOF and QqLIT, since the same analysis software was used for both instruments. However, with QqTOF, data can be retrospectively reviewed without the need to rerun samples. Second, developing a method on QqTOF was much easier and faster than on QqLIT. Collecting data in an untargeted manner does not require the user to establish compound-dependent parameters as in SRM-based methods. Although straightforward, establishing parameters for hundreds of compounds is time-consuming and must be done every time a new compound is added to the method. In addition, a slight shift in retention time in a scheduled SRM-based method can lead to the absence of data for certain compounds. These issues do not affect high-resolution methods that collect untargeted data, making them more adaptable than SRM-based techniques. This is an important consideration for the toxicology laboratory, as drug trends are constantly changing.
In summary, we compared the performance of a QqTOF instrument operating in full-scan mode with information-dependent acquisition of product ion spectra to a QqLIT instrument operating in SRM-IDA mode. We found that QqTOF performed similarly to QqLIT in identifying drugs and metabolites in 100 clinical urine samples and could serve as an alternative to SRM-based methods in broad-spectrum drug screening. There are still many challenges to implementing LC-HRMS in the clinical laboratory. Currently, the cost of these instruments is prohibitive; the technique requires highly trained staff; and determining how to appropriately analyze data, especially in suspect and untargeted screening, can be challenging. More work is needed to streamline data analysis and make HRMS more practical for the clinical setting. In addition, future studies should evaluate the clinical advantages of these additional data analysis strategies. LC-HRMS with untargeted data collection offers several advantages over SRM-based techniques. As the cost of these instruments comes down and the challenges continue to be addressed, we anticipate more clinical laboratories-especially large academic centers and reference laboratories-to adopt this technique. 
